Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.700
-0.000 (-0.01%)
Jun 29, 2026, 12:04 PM EDT - Market open
Barinthus Biotherapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Barinthus Biotherapeutics stock has a target of 7.00, which predicts an increase of 900.14% from the current stock price of 0.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 13, 2026.
Analyst Ratings
The average analyst rating for Barinthus Biotherapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Oct '25 | Nov '25 | Dec '25 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $7 | Buy | Reiterates | $7 | +900.14% | Mar 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.15
from -1.52
EPS Next Year
-1.15
from -1.15
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.15 | -1.15 | |
| Avg | -1.15 | -1.15 | |
| Low | -1.15 | -1.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.